early-symptomatic

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 47/100

   Donanemab for early symptomatic AD in the UK-indicated population: safety and efficacy in those who are non-carriers or heterozygous for APOE ε4

   ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neurodegenerative disease management · 2026-08-26 · Treatments

   In the UK-indicated population, excluding APOE ε4 homozygotes reduced, but did not eliminate, ARIA risk with donanemab.

   • Treatments
   • Side Effects
   • Clinical Trials
2. 66/100

   Attitudes of specialist memory-clinic patients with early symptomatic Alzheimer's disease towards lecanemab: results from a multicenter survey in Europe

   ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Scientific reports · 2026-07-09 · Treatments

   Before answering four binary questions, participants received brief explanatory information on expected clinical benefit, amyloid-related imaging abnormalities (ARIA), and the increased ARIA risk associated with APOE ε4 homozygosity.

   • Treatments
3. 45/100

   Practical Brain MRI Guidelines for Anti-Aβ Antibody Treatment in Early Symptomatic Alzheimer's Disease

   ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025-04-05 · Treatments

   These guidelines facilitate the accurate diagnosis and effective management of ARIA; ensure the safe administration of anti-Aβ drugs; and provide a framework for MRI facilities, includes staffing requirements and the use of MRI management systems.

   • Treatments
   • Brain Scans
   • Brain Biology

All topic tags with their study counts